Media Articles Related to Banzel (Rufinamide)
Primary data from Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy announced
Source: Clinical Trials / Drug Trials News From Medical News Today [2014.12.11]
UCB has announced the primary efficacy and safety data from the latest Phase 3 study evaluating brivaracetam (fixed doses of 100 and 200 mg/day with no up-titration) as adjunctive treatment in...
Investigational medication used to resolve life-threatening seizures in children
Source: Epilepsy News From Medical News Today [2014.11.17]
In its first clinical application in pediatric patients, an investigational medication developed and manufactured at UC Davis has been found to effectively treat children with life-threatening...
Seizures and migraines in the brain linked
Source: Headache / Migraine News From Medical News Today [2014.11.04]
Seizures and migraines have always been considered separate physiological events in the brain, but now a team of engineers and neuroscientists looking at the brain from a physics viewpoint discovered...
New mechanism for febrile seizures in young children discovered
Source: Epilepsy News From Medical News Today [2014.11.03]
Febrile seizures are among the most dreaded complications of infectious diseases in small children.
Low-carb, high-fat diets may reduce epilepsy seizures
Source: Epilepsy News From Medical News Today [2014.10.30]
Scientists find that diets high in fat and low in carbohydrates, such as the ketogenic diet or modified Atkins diet, may reduce seizures in adults with refractory epilepsy.
Published Studies Related to Banzel (Rufinamide)
Efficacy of rufinamide in drug-resistant epilepsy: a meta-analysis. [2011.05]
Rufinamide is a new orally active antiepileptic drug that has been found to be effective in the treatment of partial seizures and drop attacks associated with Lennox-Gastaut syndrome. We performed a quantitative analysis of the efficacy of this new antiepileptic drug from all double-blind, add-on, randomized, placebo-controlled clinical trials published to date.
Rufinamide for the treatment of Lennox-Gastaut syndrome. [2011.04]
INTRODUCTION: Lennox-Gastaut syndrome (LGS) is a severe treatment-resistant childhood-onset epilepsy. This review examines the role of the new drug rufinamide for the treatment of LGS...
A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. [2011.02]
PURPOSE: Efficacy and safety of adjunctive rufinamide (3,200 mg/day) was assessed in adolescents and adults with inadequately controlled partial-onset seizures receiving maintenance therapy with up to three antiepileptic drugs (AEDs)... CONCLUSIONS: Adjunctive treatment with rufinamide reduced total partial seizures in refractory patients. AEs reported were consistent with the known tolerability profile of rufinamide. Wiley Periodicals, Inc. (c) 2010 International League Against Epilepsy.
Bioavailability of three rufinamide oral suspensions compared with the marketed 400-mg tablet formulation: results from a randomized-sequence, open-label, four-period, four-sequence crossover study in healthy subjects. [2011.01]
BACKGROUND: Rufinamide is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients aged >/=4 years. OBJECTIVES: The primary purpose of this study was to compare the relative bioavailability and other pharmacokinetics of rufinamide administered as a 400-mg tablet formulation (reference) with 10 mL of a newly developed 40-mg/mL suspension (test) manufactured using 3 different homogenization speeds in healthy subjects under fed conditions. The study also explored whether homogenization speed had any effect on rufinamide pharmacokinetics when administered as a suspension formulation... CONCLUSION: This single-dose study in a small population of fed, healthy subjects found no statistically significant differences in relative bioavailability among each of the 3 test suspensions and the currently marketed 400-mg tablet formulation of rufinamide, meeting FDA and EMA regulatory requirements for assuming bioequivalence. Copyright (c) 2011 Elsevier HS Journals, Inc. All rights reserved.
Update on rufinamide in childhood epilepsy. 
Rufinamide is an orally active, structurally novel compound (1-[(2,6-difluorophenil1) methyl1]-1 hydro 1,2,3-triazole-4 carboxamide), which is structurally distinct from other anticonvulsant drugs. It was granted orphan drug status for the adjunctive treatment of Lennox-Gastaut syndrome (LGS) in the United States in 2004, and released for use in Europe in 2007.
Clinical Trials Related to Banzel (Rufinamide)
Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs [Recruiting]
Effect of Rufinamide on Chronic Postthoracotomy Pain Syndrome [Recruiting]
The purpose of this study is to test if rufinamide has an effect on chronic neuropathic pain
in patients with a post thoracotomy pain syndrome.
A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients [Recruiting]
To confirm that the combination therapy of rufinamide has superior efficacy compared to
placebo in patients with Lennox-Gastaut syndrome.
Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome [Recruiting]
This surveillance's objectives are
1. Unknown adverse reactions
2. Incidences of adverse drug reaction
3. Efficacy during long-term administration
4. Factors considered to have effect to safety and effectiveness
5. Incidences of status epileptics, skin disorders and hyper sensitivity reaction, and
central nervous system-related adverse events(ataxia , somnolence and/or dizzy, etc.)
Effect of Oral Rufinamide and Oxcarbazepine on Nerve Excitability, Hyperalgesia, Allodynia and Flare Reaction Compared to Placebo. A Monocenter, Randomized, Double-blind, Cross-over Study [Recruiting]
Untersuchungen über die Wirkmechanismen von Antiepileptika haben gezeigt, dass durch eine
Blockierung von spannungsabhängigen Natrium-Kanälen im Nervensystem die Schmerzübertragung
moduliert werden kann. Verschiedene Antiepileptika werden in der chronischen Schmerztherapie
schon lange angewendet (z. B. Oxcarbazepinum, Trileptal ® bei Trigeminusneuralgie oder
In unserer Untersuchung wollen wir zwei in der Schweiz zugelassene Antiepileptika bezüglich
ihrer Wirkung auf das Schmerzempfinden untersuchen. Eines dieser Medikamente, Trileptal®
(Wirkstoff: Oxcarbazepinum), wird schon häufig bei chronischen Schmerzzuständen eingesetzt.
Das zweite Medikament, Inovelon® (Wirkstoff: Rufinamid) ist seit mehr als einem Jahr in der
Schweiz zugelassen und wird klinisch vor allem in der Behandlung von besonderen
Epilepsieformen im Kindesalter eingesetzt. Wir erwarten, dass auch nach Gabe von InovelonÂ®
die Schmerzleitung in den Nervenzellen verÃ¤ndert und die lokalen Schmerzreaktionen in der
Haut vermindert werden.
- Trial with medicinal product
Reports of Suspected Banzel (Rufinamide) Side Effects
Pneumonia Aspiration (3),
Sudden Unexplained Death in Epilepsy (2),
Emotional Disorder (2),
Blood Potassium Decreased (2),
Confusional State (1),
Excessive Eye Blinking (1), more >>